Article
Pneumocystis jiroveci pneumonia secondary to blinatumomab therapy: a case report
2023-11-24
Abstract excerpt
<h4>Background: </h4> With the increasing use of Blinatumomab in relapsed or refractory, as well as MRD-positive, B-cell precursor acute lymphoblastic leukemia (ALL), the recognition of its adverse effects has gradually improved, in which pneumocystis jiroveci pneumonia (PCP) is rare. Case presentation We present a case of PCP in patients undergoing Blinatumomab therapy. A 70-year-old female patient diagnosed wit...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 46a0936a-5429-5b3c-b6d0-a85a184b6546
- DOI
- 10.21203/rs.3.rs-3600239/v1
